<DOC>
	<DOCNO>NCT00492271</DOCNO>
	<brief_summary>The purpose study study safety single dose multiple dos Friulimicin B healthy volunteer . The level Friulimicin B measure subject blood urine . One part study ass Friulimicin B plasma subject activity bacteria .</brief_summary>
	<brief_title>First Time Man Trial Friulimicin B</brief_title>
	<detailed_description>Continued widespread use antibiotic promote spread antibiotic resistance create urgent need antibacterial agent know cross resistance antibiotic available human . Friulimicin B show highly active range bacteria include important pathogen methicillin resistant Staphylococcus aureus ( MRSA ) , drug resistant Streptococcus pneumoniae Glycopeptide resistant Enterococcus spp . These organism causative agent serious infection skin soft tissue infection , pneumonia , bacteremia endocarditis , complicate urinary tract infection , osteomyelitis . This study first use Friulimicin B man examine safety preliminary study ass Friulimicin B plasma subject activity bacteria .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<criteria>Male female healthy subject 1855 year age In good health Abnormal physical finding clinical significance Screening examination baseline would interfere objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Friulimicin B</keyword>
	<keyword>Lipopeptide Antibiotic</keyword>
	<keyword>First Man</keyword>
</DOC>